Results 141 to 150 of about 157,911 (268)
84 Treatment of refractory right heart failure after implantation of a left ventricular assist device. is the levitronix centrimag right heart support a solution? [PDF]
B. Zych+6 more
openalex +1 more source
Abstract Aims Despite receiving guideline‐directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH‐LHD) experience higher mortality and hospitalization rates than the general HF population.
Marcin Ufnal+17 more
wiley +1 more source
Abstract Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co‐morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging.
Roy Rasalam+4 more
wiley +1 more source
Abstract Aims There are limited tools to predict long‐term mortality among patients hospitalized with acute heart failure (AHF) in China. This study aimed to develop and validate a model to predict long‐term mortality risk among patients who were hospitalized with AHF and discharged alive.
Wei Wang+8 more
wiley +1 more source
Beneficial aspects of real time flow measurements for the management of acute right ventricular heart failure following continuous flow ventricular assist device implantation [PDF]
Sotirios Spiliopoulos+3 more
openalex +1 more source
Abstract Aims Describe patient characteristics, treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs associated with patients who were diagnosed with obstructive hypertrophic cardiomyopathy (HCM) in clinical practice in England.
Faizel Osman+9 more
wiley +1 more source
Impact of continuous-flow left ventricular assist device support on right ventricular function [PDF]
Jeffrey A. Morgan+7 more
openalex +1 more source
Temporal profiling of M‐TEER‐related complications
Abstract Aims Transcatheter edge‐to‐edge repair of the mitral valve (M‐TEER) is known for its low complication rates. However, the optimal level and duration of post‐procedural care remain unclear. This study aimed to identify the specific timeframe of post‐procedural complications following M‐TEER.
Jafer Haschemi+8 more
wiley +1 more source